MedTrace Logo

Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease

NCT00002561 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 405

Last updated 2020-04-14

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. Combining more than one drug or combining chemotherapy with radiation therapy may kill more tumor cells.

PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy, with or without chemotherapy, with chemotherapy alone in treating patients with stage I or stage IIA Hodgkin's disease.

Conditions

Interventions

BIOLOGICAL

bleomycin sulfate

10 units/m2

DRUG

dacarbazine

375mg/m2

DRUG

doxorubicin hydrochloride

25mg/m2

DRUG

vinblastine

6mg/m2

RADIATION

radiation therapy

35Gy in 20 fractions (daily)

Sponsors & Collaborators

  • Eastern Cooperative Oncology Group

    collaborator NETWORK

  • NCIC Clinical Trials Group

    lead NETWORK

Principal Investigators

  • Ralph M. Meyer, MD, FRCPC · Margaret and Charles Juravinski Cancer Centre

  • Jane N. Winter, MD · Robert H. Lurie Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-01-25
Primary Completion
2011-08-15
Completion
2012-01-06

Countries

  • Canada
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002561 on ClinicalTrials.gov